Welcome to our dedicated page for Invivyd SEC filings (Ticker: IVVD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Invivyd, Inc. filings document material events, governance matters, capital actions, and financial-result disclosures for a Nasdaq-listed biopharmaceutical company developing monoclonal antibodies for serious viral infectious diseases. Recent Form 8-K reports furnish operating results, preliminary product revenue information for PEMGARDA, corporate presentations, and program updates involving COVID-19, RSV, and measles antibody candidates.
The filing record also includes a definitive proxy statement covering annual-meeting matters such as director elections and auditor ratification, as well as an 8-K describing a completed underwritten public offering of common stock and pre-funded warrants. These disclosures describe the company’s common stock, financing activity, board governance, research and development priorities, and commercial preparedness around its antibody portfolio.
Invivyd, Inc. (IVVD) received an amended Schedule 13G showing that a group of Soleus-affiliated investment entities and Guy Levy collectively report beneficial ownership below 5% of its common stock. The filing is based on an event dated December 31, 2025.
Soleus Private Equity Fund III, L.P. and related Soleus private equity entities each report beneficial ownership of 1,680,160 shares, representing 0.6% of Invivyd’s common stock. Separately, Soleus Capital Master Fund, L.P. and related Soleus capital entities each report 6,028,567 shares, or 2.2% of the class.
Soleus Capital Management, L.P., Soleus GP, LLC and Guy Levy each report beneficial ownership of 7,708,727 shares, equal to 2.8% of Invivyd’s outstanding common stock, all with shared and no sole voting or dispositive power. The percentages are calculated using 277,064,852 Invivyd shares outstanding immediately after an underwritten offering described in a prospectus supplement. The reporting persons state the securities were not acquired and are not held for the purpose of changing or influencing control of Invivyd.
Invivyd, Inc.’s Chief Financial Officer William E. Duke received a new stock option grant. On January 29, 2026, he was awarded options to purchase 625,000 shares of Invivyd common stock at an exercise price of $1.85 per share.
The options vest over three years, with 1/36th of the total vesting in substantially equal monthly installments starting one month after the grant date, contingent on his continuous service with the company.
Invivyd, Inc. reported that Chief Human Resources Officer Julie Green received a grant of stock options on January 29, 2026. The award covers 675,000 options to buy common stock at an exercise price of $1.85 per share, with no cash paid for the grant itself.
The options vest over three years, with 1/36th of the grant vesting in substantially equal monthly installments starting one month after the grant date, contingent on her continued service. Following this award, she holds 675,000 stock options directly.
Invivyd, Inc. reported a new equity award to its Chief Commercial Officer, Timothy Edward Lee. On January 29, 2026, he received a stock option to purchase 675,000 shares of common stock at an exercise price of $1.85 per share.
The option vests over three years, with 1/36th of the shares vesting in substantially equal monthly installments starting one month after the grant date, subject to his continuous service at each vesting date. Following this grant, he beneficially owns 675,000 derivative securities directly.
Invivyd, Inc. reported that its Chief Legal Officer and Secretary, Jill Andersen, received a new stock option award. On January 29, 2026, she was granted an option to buy 820,000 shares of Invivyd common stock at an exercise price of $1.85 per share.
The option vests over three years, with 1/36th of the shares vesting in substantially equal monthly installments starting one month after the grant date, conditioned on her continued service. After this grant, she beneficially owns 820,000 stock options directly.
Invivyd, Inc. granted a large stock option award to its Chief Scientific Officer. On January 29, 2026, Allen Robert D. III received a stock option covering 625,000 shares of Invivyd common stock at an exercise price of $1.85 per share.
The option vests over three years, with 1/36th of the shares vesting in substantially equal monthly installments starting one month after the grant date, conditioned on his continued service on each vesting date. Following this grant, he beneficially owns 625,000 derivative securities directly.
Invivyd, Inc. filed a current report describing a new press release that shares preliminary fourth quarter 2025 PEMGARDA® (pemivibart) net product revenue and the company’s cash and cash equivalents as of December 31, 2025. These figures are early management estimates and may change after Invivyd completes its financial closing procedures and finalizes its audited financial statements for the quarter and full year 2025.
The company explains that the preliminary data have not been audited by its independent registered public accounting firm and that additional information will be needed for a full picture of its financial position and results of operations. Invivyd also filed the full press release as an exhibit and made an updated corporate presentation available on its website, providing investors with recent business highlights alongside the early financial indicators.
Invivyd, Inc. reported that it has issued a press release announcing the selection of RSV antibody candidate VBY329, which it describes as a potential best-in-class therapy. The company stated in the release title that it is targeting investigational new drug (IND) readiness for this candidate in the second half of 2026, signaling a planned next step toward clinical development. This update was furnished as an informational 8-K under Other Events, along with the full press release as an exhibit.
Invivyd, Inc. director reports purchase of common stock
A director of Invivyd, Inc. (IVVD) reported buying 50,000 shares of common stock on 11/19/2025. The Form 4 shows a transaction code "P" for a purchase at a price of $2.50 per share. After this transaction, the reporting person beneficially owns 50,000 shares, held directly. An accompanying note explains that these shares were acquired in an underwritten public offering of Invivyd common stock.
Invivyd, Inc. entered into an underwriting agreement for an underwritten public offering of 44,000,000 shares of common stock and pre-funded warrants to purchase 6,000,000 shares. The shares were priced at $2.50 each and the pre-funded warrants at $2.4999, with an option for underwriters to buy up to an additional 7,500,000 shares at the same price. The company reports net proceeds of approximately $117.2 million after fees, and the offering closed on November 19, 2025.
Invivyd plans to use the proceeds, together with existing cash, to prepare commercially for the potential launch of VYD2311, continue research and development for programs such as RSV and measles, advance its SPEAR Study Group work on Long COVID and COVID-19 Post-Vaccination Syndrome, and for working capital and general corporate purposes. The pre-funded warrants are exercisable immediately, have no expiration, allow cash or cashless exercise, and include beneficial ownership limits generally starting at 4.99% or 9.99%, adjustable up to 19.99% with at least 61 days’ prior notice.